AltaScience

Redefining Permanent Contraception

AltaSeal®
Office-based Fallopian Tube Occlusion Device

Gavin Cooper – CEO
gavin.cooper@altascience.ie

AltaScience Inc.
Incorporated in State of Delaware US in April 2023

2025





The Team

Medical Advisory Board of Key Opinion Leaders in the US and EU.

Prof. Barbara Levy
Clinical Professor of Obstetrics and Gynecology, GW Uni School of Medicine and Health Sciences, UCSD Health, California, USA

Prof. Linda Bradley
Professor Obstetrics, Gynecology and Reproductive Biology, Cleveland Clinic, Cleveland, Ohio, USA

Dr Kelly Wright
Director of Minimally Invasive Gynecologic Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA

Dr. Andreas Thurkow
Consultant Gynecologist in minimally invasive surgery, Amsterdam Medical Centre, The Netherlands

Dr Edward Evantash
Principal Consultant for Clinical Affairs, Cambridge Medical Affairs, Cambridge, MA, USA

Experienced AltaScience Management Team

Gavin Cooper
Chief Executive Officer

Conor Dalton
Chief Financial Officer

Dr. James Coleman
Founder, Medical Director

Stephen O'Sullivan
Operations Director

Triona McNicholl
Quality & Reg. Affairs

AltaScience Investment Highlights

1

Category leading medical device

30-minute Day Case, No Hormones, No Anesthesia

2

Large, growing, and reimbursed Market

$2.4 Billion Market
1.5m procedures with CPT codes in place

3

Clear path to market approvals

FDA MD EU-MDR

SAB of World-Renowned KOLS

4

Strong safety and efficacy record. IP protected platform

Proven Device Platform
7 years of Clinical Data

5

Proven robust manufacturing process

High gross margins
(› 80%)

AltaScience's mission is to be category leader in permanent contraception market

US Market Size p.a.

Worldwide 219 Million Women rely on Female Sterilization.
(24% of all Contraception Users).

Our Vision

#1

Creating category leading device

The Problem

1.5 Million

Projected cases annually

- 1000k sterilizations
- 500k Endometrial ablations

45%

of **6M** annual pregnancies in US are unintended

Our Solution

90 Patients

Proven Technology

- Across 3 studies
- out to **7** years
- No pregnancies

$2.4 Billion Total Addressable Market (TAM) (1.5M cases x $1600)

AltaScience

Patient request for permanent contraception has increased since Roe V Wade US Court Judgement Reversal

Figure. Monthly Time Series of Tubal Ligation and Vasectomy Procedure Rates Among Adults Aged 18 to 30 Years



Published: April 12, 2024. doi:10.1001/jamahealthforum.2024.0424

AltaScience

How we deliver leadership in Permanent Contraception

Today

Tubal Ligation



- **Cauterized, Tied, Cut and Banded**
- **Operating Room Procedure**
- Large Associated Cost
- Scars, Anesthesia, Infections
- Not suitable for high BMI
- Failure rate: 1.3 -6%
- 2–3-day recovery
- 90-Year-Old Procedure

Tomorrow

AltaSeal device and implant



- ✓ **No Surgical Incision**
- ✓ **Office Procedure in 30 minutes**
- ✓ Cost Effective
- ✓ No Anesthesia, No Hormones, No Scars
- ✓ Suitable for high BMI
- ✓ No Pregnancies
- ✓ Quick recovery - hours
- ✓ Proven platform & modern technique

Benefits of AltaSeal® Over Alternative Birth Control Options

	Altaseal	Tubal Sterilization Surgery	Hormonal Implant	IUD (Copper/ Hormonal)	Essure (Off Market)
Permanent	✓	✓	✗	✗	✓
Office – based Procedure	✓	✗	✓	✓	✓
No Anesthesia	✓	✗	✓	✓	✓
No Hormones	✓	✓	✗	✓ ✗	✓
IVF Still Possible	✓	✓	✓	✓	✓
Patient-device compatibility / biocompatibility	✓	✓	✓	✓	✗ Leading to Market Recall
Failure Rate	0% - to date (See Clinical Results)	1-3* - 6% ** (after 3- 5 Years)	8%	1-3%	1%† - 5%** (after 3- 5 Years)

*. Ref: Peterson, et al; The risk of pregnancy after tubal sterilization: Findings from the U.S. Collaborative Review of Sterilization; AM J OBSTET GYNECOL 1996;174:1161-70

** Ref: Gariepy, et al; Fertility and Sterility® Vol. 117, No. 6, June 2022.

† Result from Essure Post Market Surveillance Study PS160001 - https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm?t_id=356&c_id=3854

AltaScience

Emerging Competitor

FemBloc is undertaking an FDA IDE process.

FemBloc is in clinical stage hysteroscopic, office-based approach to permanent birth control.

Inflammatory response Vs Mechanical occlusion.

Blind Procedure Vs Direct Vision.

Altaseal has clear advantages and preferred by clinicians in our research.





- Single arm, multi-center study
- 401 Patients to be enrolled
- Ultrasound Confirmation of Occlusion at 3-months
- Study commenced in September 2023

CPT Reimbursement Code For Hysteroscopic Sterilization Currently Exists



$5866

Tubal Ligation

- Invasive Surgical Procedure
  Requires Operating Room (OR)
- 1.3% to 6% Failure Rate
- 3-4 Day Recovery
- CPT† Code 58617
  OR $5866

AltaSeal®

- Non – Invasive
  Office-based Procedure
- 0% Failure Rate for 90 Women. 7 yrs Reliance Data
- 1-2 Hours Recovery
- CPT† Code 58565
  Office $3048



$3048

Sales Price: $1600

AltaScience

†CPT: Current Procedural Terminology

The AltaSeal® Implant Results in Permanent, Female Contraception, via Hysteroscopic Delivery

- Ambulatory office-based 30-minute procedure – oral analgesia
- Permanent implant: metallic biomaterial
- Atraumatic & easy-to-use
- Placed in the fallopian tubes by a gynecologist using a hysteroscope.
- The implant mechanically blocks the fallopian tube thus preventing pregnancy.
- Currently no Hysteroscopic Permanent Contraception Device on the Market.



AltaSeal® Fallopian Tube Occlusion Implant

AltaSeal® Delivery System



- ✓ Pre-mounted implant
- ✓ **Easy to use device**
- ✓ Effective when deployed
- ✓ **Patent Claims directed to implant and method**



Deployed Implant

Strong Portfolio of granted US, EU, JP and CN patents including;

- Actuator for deployable implant [US Patent # 9,603,600]
- Devices and methods for occluding or promoting fluid flow (continuation) [US Appln #18/144,817 ; US Patent #11,672,517]

Coverage to December 2035.

Further applications pending.

- Wound Closure and Tissue Coupling Systems and Methods [US Appln #18/087,498]
- Wound Closure and Tissue Coupling Systems and Methods [US Appln #18/087,559]
- Wound Closure and Tissue Coupling Systems and Methods [US Appln #18/977,902]

Video Showing Deployment

Critical Aspect: Ultrasound Confirmation Check at 3-months



Pre AltaSeal® Procedure



Post AltaSeal® Procedure
with x-ray HSG



AltaScience

Confirmation test will be performed using Ultrasound HyFoSy { ExEm® Foam } instead of x-ray HSG, in-line with improvements in best standard of care

- https://pubmed.ncbi.nlm.nih.gov/33368463/
- https://www.sciencedirect.com/science/article/pii/S1472648324005698
- https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/uog.17398

Further Clinical Applications of AltaSeal®

Use with Endometrial Ablation

500k Cases Per Annum in US

Use with In-Vitro Fertilization (IVF)

50k Cases Per Annum in US

Up to 30% of women with infertility have hydrosalpinx as a cause.

The Solution

- AltaSeal can occlude the fallopian tube(s), stopping the fluid from entering the uterine cavity from the hydrosalpinx and damaging the embryo during IVF (greatly increasing chance of full-term pregnancy).

Clinical Effectiveness

- 17 women received AltaSeal® prior to IVF.
- 10 healthy babies were born to 8 women.

Excellent AltaSeal® Clinical Data

- Combination of 3 clinical studies
- 90 women relying on AltaSeal® for up to 7 years*

  * { > 5000 months cumulative}

- 0 pregnancies in patients with proven occlusion and advised to rely.
- Excellent Safety Profile

AltaScience

AltaSeal® EU-MDR Regulatory Pathway for CE-Mark

EU-MDR Pathway:

- Single arm, multi-center study
- Ca. 220 Patients to be enrolled – with ca. 180 to 12-Month Pregnancy Endpoint
- Ultrasound Confirmation of Occlusion at 3-months in Pivotal

MD

EU-MDR

Pilot (UK)

Class III Permanent Implant

Multi-Center

Non-Randomized, single arm Trial

180 Patients

Primary End points

Pregnancy Rate @ 12 Months

Safety – Adverse events @ 12 months

Same participants for European Clinical supporting CE-Mark as for FDA IDE supporting PMA

AltaSeal® US PMA Regulatory Pathway

PMA Regulatory Pathway based on Competitor IDE approval:

- Initiates after Pilot Study (UK)
- Single arm, multi-center study
- Ca. 500 Patients to be enrolled – with ca. 366 to 12-Month Pregnancy Endpoint
- Ultrasound Confirmation of Occlusion at 3-months



Same participants for IDE supporting PMA as for European Clinical supporting CE-Mark

AltaScience Funding Strategy and Milestones



Use of Funds

A
FDA and CE Clinical Approval to start studies

B
CE Mark Recruitment Completed (n = 220 Pts)

C
FDA Recruitment Complete (n = 500 Pts)

D
Market Launch Expenses - Q4 2029

Total : $20M

$4m of Convertible Loan Note (CLN) finances development program to achieve FDA IDE And CE-Mark Pivotal Trial Initiation

AltaScience Investment Highlights

1

Category leading medical device

30-minute Day Case, No Hormones, No Anesthesia

2

Large, growing, and reimbursed Market

$2.4 Billion Market
1.5m procedures with CPT codes in place

3

Clear path to market approvals

FDA MD EU-MDR

SAB of World-Renowned KOLS

4

Strong safety and efficacy record. IP protected platform

Proven Device Platform
7 years of Clinical Data

5

Proven robust manufacturing process

High gross margins
(› 80%)

AltaScience's mission is to be category leader in permanent contraception market